gyki 52466 has been researched along with Dyskinesia Syndromes in 1 studies
GYKI 52466: an AMPA (non-NMDA) receptor antagonist; structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " injections at 1-h intervals, the first dosage was given shortly after the intrastriatal injection of (S)-alpha-amino-3-hydroxy-5,7-methylisoxazole-4-propionic acid (AMPA) (2." | 1.31 | Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats. ( Banczerowski-Pelyhe, I; Gulyás-Kovács, A; Takács, J; Tarnawa, I; Világi, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Világi, I | 1 |
| Takács, J | 1 |
| Gulyás-Kovács, A | 1 |
| Banczerowski-Pelyhe, I | 1 |
| Tarnawa, I | 1 |
1 other study available for gyki 52466 and Dyskinesia Syndromes
| Article | Year |
|---|---|
Protective effect of the antiepileptic drug candidate talampanel against AMPA-induced striatal neurotoxicity in neonatal rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Animals, Newborn; Anti-Anxiety Ag | 2002 |